Randomized Trialhigh evidence
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet (London, England)·September 5, 2026·PMID 42664979
Why it mattersElevated lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, and current lipid-lowering therapies have limited effect on Lp(a). Kylo-11 offers a potential long-duration treatment option, with a single dose providing sustained Lp(a) reduction for up to 48 weeks.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled